The first line of treatment for kidney cancer is immunotherapy using drugs such as PD-L1 checkpoint inhibitors. However, the procedure is expensive and helps only a subset of patients and for the majority of patients it goes futile. Now, researchers have conducted a study to predict the response of kidney cancer to immunotherapy using Lucence's molecular test, CLEARScore™.
CLEARScore™ is a molecular test that predicts treatment response for kidney cancer. It is an algorithm involving eight genes in the tumor, which classifies kidney cancer by molecular type. This test has been used to successfully predict treatment response of kidney cancer patients to tyrosine kinase inhibitors, a type of targeted therapy. The results were published in 2015 in European Urology, the world's top urology journal.
Renal Cell Carcinoma
Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages of the cancer are asymptomatic and this makes early management of the disease difficult.
Advertisement
‘CLEARScore™ assists in identifying whether a kidney cancer patient will or will not benefit from immunotherapy.’
Tweet it Now
In this new study, CLEARScore™ was investigated in correlation with anti-PD-L1 inhibitors and immune cell markers in 36 kidney cancer patients. The results showed that the gene expression score of the eight genes correlated with immune cell infiltration and clinical response to anti-PD-L1 inhibitors in a subset of patients. This indicates that multigene score should be investigated as a biomarker to select patients who are likely to respond to immunotherapy. The study was conducted by National Cancer Centre Singapore and Lucence Diagnostics, in collaboration with the Diagnostics Development (DxD) Hub led by A*ccelerate (A*STAR), Singapore General Hospital and OncoCare Cancer Centre.
"Immunotherapy is a major breakthrough in our battle against kidney cancer. It is however expensive and may have side effects. Having a test that can distinguish whether a kidney cancer patient will or will not benefit from anti-PD-L1 immunotherapy would be of high clinical value. Such tests have not been previously reported, and CLEARScore™ is a promising and exciting advance towards more precise selection of cancer patients for treatment,'' said Dr Ravindran Kanesvaran, Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore, who designed and led the study.
![Radiofrequency Ablation (RFA) of Kidney Tumors]( "Radiofrequency Ablation (RFA) of Kidney Tumors")
Radiofrequency ablation (RFA) is a medical procedure that uses electrical energy and heat to destroy cancer cells. Know more about the benefits and risks of RFA.
"This is the first study to report the correlation of a multigene score with immune phenotypes in kidney cancer. We are excited about the potential of using our CLEARScore™ test to help kidney cancer patients avoid futile treatments and prolong their lives. To further establish the clinical utility of this test for immunotherapy, we will be conducting a multinational study on a larger cohort of kidney cancer patients,'' said Dr Yukti Choudhury, Chief Technology Officer, Lucence Diagnostics, who will be presenting the study at ASCO GU. Kidney cancer is among the ten most common cancers in men and women across the world. In 2018, there were over 400,000 new cases of kidney cancer globally.
Source: Eurekalert
Radiofrequency Ablation (RFA) of Kidney Tumors
Radiofrequency ablation (RFA) is a medical procedure that uses electrical energy and heat to destroy cancer cells. Know more about the benefits and risks of RFA.
Advertisement
"This is the first study to report the correlation of a multigene score with immune phenotypes in kidney cancer. We are excited about the potential of using our CLEARScore™ test to help kidney cancer patients avoid futile treatments and prolong their lives. To further establish the clinical utility of this test for immunotherapy, we will be conducting a multinational study on a larger cohort of kidney cancer patients,'' said Dr Yukti Choudhury, Chief Technology Officer, Lucence Diagnostics, who will be presenting the study at ASCO GU. Kidney cancer is among the ten most common cancers in men and women across the world. In 2018, there were over 400,000 new cases of kidney cancer globally.
Source: Eurekalert
Wilms Tumor
Wilms tumor or nephroblastoma is the most common cancerous kidney tumor in children of less than 5 years of age. Most children with favorable histology can be cured of the cancer.
Advertisement
 Cancer ImmunotherapyCancer immunotherapy is a new advancement in cancer treatment that uses certain components of a person''s immune system to fight against cancer cells. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
Colon cancer's hidden link revealed in microbiome study.
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.
Scientists are making strides in personalized breast cancer therapy by developing a highly accurate molecular classifier test for breast cancer patients.
Experts suggest high-income countries implement a comprehensive risk-based approach for prostate-specific antigen (PSA) testing to reduce overdiagnosis and overtreatment.